VEA
HARP

Virtus ETF Advisers’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Virtus ETF Advisers’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,377
Closed -$109K – 408
2021
Q3 		$109K Sell
1,377
-72
-5% -$7.24K 0.05% 377
2021
Q2 		$201K Sell
1,449
-676
-32% -$129K 0.08% 344
2021
Q1 		$445K Buy
2,125
+37
+2% +$7.42K 0.19% 164
2020
Q4 		$347K Buy
2,088
+340
+19% +$52.5K 0.14% 170
2020
Q3 		$297K Sell
1,748
-238
-12% -$34.3K 0.16% 226
2020
Q2 		$330K Buy
+1,986
New +$310K 0.16% 287

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Virtus ETF Advisers's HARP Position: Q4 2021 in Review

Virtus ETF Advisers sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2021, closing a stake of 1,377 shares — an estimated $109K sold.

Virtus ETF Advisers first reported a position in HARP in Q2 2020 and held it in 6 quarters. The position peaked at $445K in Q1 2021. 84 funds tracked by Wall St. Rank hold HARP as of Q4 2021.

  • Virtus ETF Advisers reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 1,377 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $109K.
  • Virtus ETF Advisers first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • Virtus ETF Advisers's Harpoon Therapeutics, Inc. Common Stock position peaked at $445K in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.